Bharat Biotech Justifies Trial Site Shifts For Tetravalent Vaccine
Executive Summary
Trial-related challenges in India appear to have pushed vaccine maker Bharat Biotech towards opting for alternative sites for studies on its tetravalent vaccine. The firm says it has justified its position to the regulator, though some experts advise diligence in site selection.
You may also be interested in...
Bharat Biotech Gets WHO Nod For ‘Game-Changer’ Typhoid Vaccine
India’s Bharat Biotech has won WHO pre-qualification for a vaccine against typhoid fever that experts say will be a “game-changer” in preventing the bacterial disease, especially among children under two years - the age group most at risk.
Serum Leads Way With Heat-Stable Rotavirus Vaccine But Competition Unfazed
Serum Institute has launched a cut-price oral thermostable rotavirus vaccine in India, but competitors like Hilleman Labs, also developing a heat-stable vaccine in the area, aren’t losing much sleep, for now at least. Serum has also introduced a rabies monoclonal antibody.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.